In this interactive session, experts focus on the diagnosis of clinically significant hypersplenism, related clinical complications, and management approaches including emerging interventional approaches to clinically important hypersplenism.
RNA nanomedicine has emerged as a groundbreaking approach for safely delivering genetic instructions into target cells, enabling their reprogramming without degradation. Its significance was underscored during the COVID-19 pandemic with the successful deployment of mRNA-based vaccines formulated using lipid nanoparticles. These nanoparticles, available in various formulations, act as carriers to transport RNA directly into target cells for therapeutic action. Patisiran and lumasiran—2 FDA-approved RNA interference (RNAi) agents delivered via lipid nanoparticles (RNA nanotherapeutics)—exemplify this new generation of targeted therapies. These treatments have significantly reduced the need for liver transplantation in patients with genetic conditions such as amyloidosis and hyperoxaluria. Consequently, referrals for liver transplantation due to these metabolic disorders have dramatically declined, highlighting the transformative potential of RNA nanomedicine in clinical practice. In this workshop, experts review the transformative world of RNA nanomedicine; explore its role in delivering genetic instructions with unparalleled precision; discover how advancements in lipid nanoparticle (LNP) formulations are enabling breakthrough therapies; and gain insights into the latest clinical applications that are reshaping treatment paradigms, such as reducing the need for liver transplantation in genetic and metabolic disorders.
Begin your experience at The Liver Meeting® with an evening of mingling, refreshments, and a warm welcome from AASLD as you explore the Exhibit Hall. This casual gathering provides the opportunity to meet new colleagues and hear from industry leaders.
Sponsored by: Mirum Pharmaceuticals
Join experts providing a comprehensive overview of MetALD, ie, combined metabolic dysfunction-associated and alcohol-associated liver disease. Presenters highlight key considerations for developing robust research programs; leveraging biomarkers and omics technologies; and understanding the interplay between alcohol use, metabolic dysfunction, and liver disease progression. Speakers discuss emerging insights into risk stratification, cohort development, and the relationship between MetALD and HCC. The workshop aims to integrate translational and clinical research approaches, equipping attendees with knowledge to enhance precision medicine strategies in MetALD.
Join your SIG Meet-Up, where you can connect with professionals who share your research and clinical interests! Enjoy light snacks, fun games, and great conversations in a relaxed, informal setting—perfect for networking and building new connections.
Experts provide an overview of the latest innovations in study design in MetALD-induced liver disease, including study endpoints. Presenters explore how to design and conduct effective cohort studies, large database studies, and clinical trials. Topics include the role of investigator-initiated cohort studies, large national database studies, and clinical trials in MetALD with discussion of funding opportunities, monitoring, and conducting these studies with a focus on early-stage investigators. This interactive session provides an opportunity to discuss study methodologies, existing studies, and protocols with the moderators.
Experts provide an overview of the latest innovations in study design in MetALD-induced liver disease, including study endpoints. Presenters explore how to design and conduct effective cohort studies, large database studies, and clinical trials. Topics include the role of investigator-initiated cohort studies, large national database studies, and clinical trials in MetALD with discussion of funding opportunities, monitoring, and conducting these studies with a focus on early-stage investigators. This interactive session provides an opportunity to discuss study methodologies, existing studies, and protocols with the moderators.
America’s dominance in medical research over the last few decades has been remarkable, with exponentially increasing advances that have saved millions of lives and reduced suffering. Yet dark clouds are now around us. NIH support for basic and translational research in US research universities is under attack. And even for breakthroughs that have happened, our broken health care system is not always able to deliver therapies for conditions like sickle cell anemia and hepatitis C. But there is hope. Americans are waking up to the fact that these attacks on medical research are not what they want for themselves and their families, and creative solutions are being developed to deliver cures to those who need them.
Subject matter experts compare and contrast the different types of cell death in homeostasis and liver injury, such as apoptosis, necrosis, autophagy, necroptosis, ferroptosis, and pyroptosis, among others. Topics include: characterization of identification of the different modalities of cell death; the role of cell death in various liver diseases; signaling cascades and molecular mechanisms of cell death; and potential therapeutic strategies.
A hallmark symptom of cholestasis is pruritus, which can be severe and debilitating for many patients, significantly negatively impacting their quality of life. Experts present information focused on established and recently approved therapies to treat pruritus in cholestatic diseases. Speakers highlight a multistep approach to therapeutic options in pruritus, including alternative strategies in the settings of medication intolerance and difficult-to-treat pruritus.